Switch theme
Sign up to access all valuation multiples
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
1999
10.3K+
LTM Revenue $4.3B
LTM EBITDA $1.2B
$31.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
DexCom has a last 12-month revenue (LTM) of $4.3B and a last 12-month EBITDA of $1.2B.
In the most recent fiscal year, DexCom achieved revenue of $4.0B and an EBITDA of $946M.
DexCom expects next 12-month revenue of XXX and NTM EBITDA of XXX
See DexCom valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.3B | XXX | $4.0B | XXX | XXX | XXX |
| Gross Profit | $2.7B | XXX | $2.4B | XXX | XXX | XXX |
| Gross Margin | 62% | XXX | 60% | XXX | XXX | XXX |
| EBITDA | $1.2B | XXX | $946M | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 23% | XXX | XXX | XXX |
| EBIT | $855M | XXX | $600M | XXX | XXX | XXX |
| EBIT Margin | 20% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $730M | XXX | $576M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 14% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $1.8B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of June 20, 2025, DexCom's stock price is $80.
DexCom has current market cap of $31.4B, and EV of $31.3B.
See DexCom trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $31.3B | $31.4B | XXX | XXX | XXX | XXX | $1.82 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of June 20, 2025, DexCom has market cap of $31.4B and EV of $31.3B.
DexCom's trades at 7.7x EV/Revenue multiple, and 33.0x EV/EBITDA.
Equity research analysts estimate DexCom's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
DexCom has a P/E ratio of 43.0x.
See valuation multiples for DexCom and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $31.4B | XXX | $31.4B | XXX | XXX | XXX |
| EV (current) | $31.3B | XXX | $31.3B | XXX | XXX | XXX |
| EV/Revenue | 7.3x | XXX | 7.7x | XXX | XXX | XXX |
| EV/EBITDA | 25.4x | XXX | 33.0x | XXX | XXX | XXX |
| EV/EBIT | 36.6x | XXX | 52.1x | XXX | XXX | XXX |
| EV/Gross Profit | 11.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 43.0x | XXX | 54.4x | XXX | XXX | XXX |
| EV/FCF | 42.9x | XXX | 49.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDexCom's last 12 month revenue growth is 15%
DexCom's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
DexCom's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
DexCom's rule of X is 66% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for DexCom and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 23% | XXX | 22% | XXX | XXX | XXX |
| Rule of 40 | 40% | XXX | 38% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 66% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 14% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 46% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
DexCom acquired XXX companies to date.
Last acquisition by DexCom was XXXXXXXX, XXXXX XXXXX XXXXXX . DexCom acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was DexCom founded? | DexCom was founded in 1999. |
| Where is DexCom headquartered? | DexCom is headquartered in United States of America. |
| How many employees does DexCom have? | As of today, DexCom has 10.3K+ employees. |
| Who is the CEO of DexCom? | DexCom's CEO is Mr. Kevin R. Sayer, C.P.A.. |
| Is DexCom publicy listed? | Yes, DexCom is a public company listed on NAS. |
| What is the stock symbol of DexCom? | DexCom trades under DXCM ticker. |
| When did DexCom go public? | DexCom went public in 2005. |
| Who are competitors of DexCom? | Similar companies to DexCom include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of DexCom? | DexCom's current market cap is $31.4B |
| What is the current revenue of DexCom? | DexCom's last 12 months revenue is $4.3B. |
| What is the current revenue growth of DexCom? | DexCom revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of DexCom? | Current revenue multiple of DexCom is 7.3x. |
| Is DexCom profitable? | Yes, DexCom is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of DexCom? | DexCom's last 12 months EBITDA is $1.2B. |
| What is DexCom's EBITDA margin? | DexCom's last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of DexCom? | Current EBITDA multiple of DexCom is 25.4x. |
| What is the current FCF of DexCom? | DexCom's last 12 months FCF is $728M. |
| What is DexCom's FCF margin? | DexCom's last 12 months FCF margin is 17%. |
| What is the current EV/FCF multiple of DexCom? | Current FCF multiple of DexCom is 42.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
